Tumor heterogeneity and circulating tumor cells.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer treatment relies on molecular biomarkers, but tumor heterogeneity complicates personalized strategies.
• Genetic instability leads to tumor heterogeneity, impacting diagnostic precision and therapeutic efficacy.
• Heterogeneity exists within primary tumors, between metastases, and between primary and metastatic sites.

Purpose of the Study:

• To review the efficacy of circulating tumor cells (CTCs) in identifying spatial and temporal tumor heterogeneity.
• To explore CTCs as a tool for comprehensive assessment of cancer mutations and protein expression.
• To highlight current challenges and future applications of CTC analysis in oncology.

Main Methods:

• Review of existing literature on circulating tumor cells (CTCs) and tumor heterogeneity.
• Analysis of studies utilizing CTCs for molecular profiling and monitoring of cancer evolution.
• Evaluation of CTCs as a minimally invasive alternative to tissue biopsies.

Main Results:

• CTCs can capture the genetic and protein expression diversity of a tumor, reflecting both spatial and temporal heterogeneity.
• CTC analysis provides a dynamic, minimally invasive approach to monitor tumor evolution compared to static tissue biopsies.
• CTCs hold potential for a comprehensive representation of the full spectrum of cancer alterations.

Conclusions:

• Circulating tumor cells show significant potential for assessing tumor heterogeneity in cancer patients.
• CTC analysis offers a minimally invasive strategy for dynamic monitoring of cancer progression and treatment response.
• Further research is needed to overcome current challenges and fully realize the clinical utility of CTCs in personalized oncology.